Meeting
2018 ASCO Annual Meeting
A phase I study of AL101, a pan-NOTCH inhibitor, in patients (pts) with locally advanced or metastatic solid tumors.
Authors
Anthony B. El-Khoueiry
University of Southern California Norris Comprehensive Cancer Center, Los Angeles, CA
Anthony B. El-Khoueiry , Jayesh Desai , Swaminathan Padmanabhan Iyer , Shirish M. Gadgeel , Suresh S. Ramalingam , Leora Horn , Patricia LoRusso , Gaurav Bajaj , Georgia Kollia , Zhenhao Qi , Shashwati Basak , Bruce S. Fischer , Matti Davis , Philippe L. Bedard
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Discussion Session
Session Title
Developmental Therapeutics—Clinical Pharmacology and Experimental Therapeutics
Track
Developmental Therapeutics and Translational Research
Sub Track
Small Molecules
Clinical Trial Registration Number
NCT01292655
Citation
J Clin Oncol 36, 2018 (suppl; abstr 2515)
DOI
10.1200/JCO.2018.36.15_suppl.2515
Abstract #
2515
Poster Bd #
341
Abstract Disclosures
Similar Posters
Poster
2018 ASCO Annual Meeting
A phase I study of a novel IAP inhibitor APG-1387 in patients with advanced solid tumors.
First Author: Ruihua Xu
Poster
2016 Gastrointestinal Cancers Symposium
A phase I trial with cohort expansion of BYL719 in combination with gemcitabine and nab-paclitaxel in locally advanced and metastatic pancreatic cancer.
First Author: Heloisa P. Soares
Poster
2015 ASCO Annual Meeting
Phase I study of receptor tyrosine kinase (RTK) inhibitor, MGCD265, in patients (pts) with advanced solid tumors.
First Author: Christian K. Kollmannsberger
Poster
2013 ASCO Annual Meeting
A phase I dose-escalation study of volasertib (BI 6727) combined with nintedanib (BIBF 1120) in advanced solid tumors.
First Author: Filippo G. De Braud